This is the authors' abstract. We don't add key points for this paper.
Inflammatory bowel disease (IBD) is a chronic as well as recurrent intestinal disease, in addition to has become a main worldwide health botheration. Persons with IBD face an escalated risk of generating colorectal cancer(CRC), along with recent studies have pointed that mitochondrial impairment possesses a vital part in the pathogenesis of both IBD as well as CRC. This review summarizes the pathogenesis of IBD in addition to CRC, concentrating on mitochondrial impairment, as well as examines pharmacological targets in addition to approaches for tackling both situations by manipulating mitochondrial working. Additionally, recent advancements in the pharmacological manipulation of mitochondrial impairment for therapy of IBD , along with CRC, incorporating mitochondrial injury, liberation of mitochondrial DNA (mtDNA), as well as dysfunction of mitophagy, are exhaustively covered. The review further yields a systematic overview of natural substances (for instance flavonoids, alkaloids, in addition to diterpenoids), Chinese medicines,along with intestinal microbiota, which possess the capability of attenuating IBD as well as ameliorate the propagation of CRC by manipulating mitochondrial working. In the future, it will be essential to generate greater practical technologieses for real-time monitoring in addition to, along with exactitude determination of mitochondrial working, which will greatly help scientists in isolating greater efficacious substances for therapy of IBD as well as CRC via manipulation of mitochondrial working.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kulvinder Kochar Kaur (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: